Vol. 6 No. 9 (2026): September
Reimbursement Reviews

Avapritinib (Ayvakyt)

decorative image of the issue cover

Published September 9, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Avapritinib (Ayvakyt), 25 mg tablets, oral administration.
  • Indication:
    • Ayvakyt (avapritinib tablets) is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment.
    • Ayvakyt is not recommended for the treatment of patients with platelet counts of less than 50 × 109/L.